Wall Street expects Regeneron to report Q3 2026 consensus revenue of $4.56 billion and adjusted EPS of $16.19, while the stock currently trades near $810 against an average analyst target of $857.
The primary focus for investors is the Sanofi collaboration, as this marks the first quarter Regeneron will book its full share of Dupixent profits following the final repayment of its $3.1 billion development balance.
This accounting shift is expected to significantly bolster collaboration revenue and overall margins. Analysts are also closely monitoring the commercial ramp of Eylea HD as it continues to replace the legacy formulation amidst increasing biosimilar competition.